Bradley J. Bolzon PhD - 24 Feb 2021 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
Director, 10%+ Owner
Signature
/s/ Ajim Tamboli, Attorney-in-Fact
Issuer symbol
GLUE
Transactions as of
24 Feb 2021
Net transactions value
+$15,149,998
Form type
4
Filing time
25 Jun 2021, 17:00:33 UTC
Next filing
14 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLUE Series B convertible preferred stock Award $3,000,000 +1,500,000 +100% $2.00 3,000,000 24 Feb 2021 Common Stock 424,869 By Versant Capital VI, L.P. F1, F2, F3
transaction GLUE Series B convertible preferred stock Award $4,150,000 +2,075,000 +100% $2.00 4,150,000 24 Feb 2021 Common Stock 587,735 By Versant Vantage I, L.P. F1, F2, F4
transaction GLUE Series C convertible preferred stock Award $7,999,998 +2,699,328 $2.96 2,699,328 11 Mar 2021 Common Stock 764,573 By Versant Vantage I, L.P. F1, F2, F4
transaction GLUE Stock Option (Right to Buy) Award $0 +47,132 $0.000000 47,132 23 Jun 2021 Common Stock 47,132 $19.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date.
F2 This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3.
F3 Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F4 Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F5 This option shall vest in 36 substantially equal monthly installments, with the first installment vesting on June 28, 2021.